ArticleBMC urology2026
Depression, anxiety, and health related quality of life following radical prostatectomy and radiation treatment: 12 month outcomes in a South African cohort.
Article in BMC urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeLongitudinal patient-reported outcomes comparing radical prostatectomy (RP) and radiation (RT) for localized prostate cancer (CaP) in low- to middle- income countries are limited. We examined the comparative course of depression and anxiety and their association with health related quality of life (HRQOL) in men treated with RP or RT over a year post-treatment.
methodsData from 161 South African (SA) men with CaP were analysed. Depression, Anxiety, HRQOL, and relevant covariates were measured at baseline, 3, 6, 9, and 12 months. We used the following validated scales: Centre for Epidemiologic Studies Depression (CES-D), State Trait Anxiety Inventory (STAI-S), European Organisation for Research and Treatment in Cancer Quality of Life (EORTC QLQ-PR25), Multidimensional Scale of Perceived Social Support (MSPSS), Memorial Anxiety Scale for Prostate Cancer (MAX-PC), Connor-Davidson Resilience Scale (CD-RISC), and Decisional Conflict Scale (DCS).
resultsDepressive symptoms (CES-D ≥ 16) remained elevated 12 months post-RP (baseline: 43%; 3-month: 37%; 6-month: 47%; 12-month: 42%), while RT prevalence declined (39% to 29%). Similarly, anxiety (STAI-S ≥ 39) was more prevalent and persistent in the RP group (29% to 23%; 6-month peak: 28%) compared to the RT group (26% to 15%), where scores consistently declined throughout the first year. Overall urinary morbidity was marked in the first six months (β = 11.828; 95% CI: 7.931to 15.73; p < 0.001). More men in the RP group exhibited higher incontinence aids use (β = -21.477; 95% CI: to 33.261 to 9.694; p < 0.001). Sexual function in RP was lower (β = 18.006; 95% CI: 6.881 to 29.131; p = 0.002) with increased sexual activity from month nine onwards (β = -13.203; 95% CI: -23.489 to -2.916; p = 0.012). RT was associated with bowel symptoms in the latter half of follow-up. (4.681; 95% CI: 0.702 to 8.659; p = 0.021). Depression and anxiety adversely affected all HRQOL functional and symptom domains except sexual activity.
conclusionThe high prevalence of depression and anxiety reflects marked psychological morbidity in men treated for CaP in the first year post-treatment. Given the substantial association between psychological impairment and HRQOL, integrating mental health screening, management and referral into uro-oncology protocols is critical.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.